Enrollment Discontinued For Exelixis-Licensed Oncologic
This article was originally published in The Pink Sheet Daily
Executive Summary
Becatecarin was in Phase III for hepatobiliary tumors under license to Swiss firm Helsinn.
You may also be interested in...
Bristol-Myers Squibb Builds On Exelixis Collaboration
Bristol will choose three of Exelixis' pre-IND oncology candidates for a 50/50 development and commercialization deal.
Bristol-Myers Squibb Builds On Exelixis Collaboration
Bristol will choose three of Exelixis' pre-IND oncology candidates for a 50/50 development and commercialization deal.
Despite Enrollment Suspension, Exelixis Optimistic On XL999
Tyrosine kinase inhibitor is one of a dozen compounds GlaxoSmithKline can option.